05 Feb 2026 Earnings: iX Biopharma (42C.SI, SES) S$0.17 ahead of report

iX Biopharma (42C.SI) trades at S$0.17 on the Singapore Exchange (SES) as markets watch an earnings announcement due 06 Feb 2026. The upcoming report is the immediate catalyst for intraday flows and liquidity, with 6,303,600 shares trading today and a 50-day average of 0.15. We focus on how short-term technicals, cash flow metrics and clinical-development milestones could move 42C.SI stock into earnings week

Earnings calendar and near-term catalyst for 42C.SI stock

Earnings release scheduled for 06 Feb 2026 is the primary near-term catalyst. Management commentary on product sales, clinical updates for Wafermine and Wafer-based pipelines, and guidance will drive intraday volatility. Analysts and traders will watch revenue, cash burn and any mention of U.S. or China commercial traction. For context we note the company lists on SES in Singapore and operates in Healthcare, Drug Manufacturers – Specialty & Generic.

Q4 preview and what to expect in the 42C.SI earnings report

We expect the report to show continued R&D spending and negative EPS. Last twelve months EPS is -0.01 and PE is -17.10, signaling losses. Revenue per share TTM is 0.01 and R&D to revenue is 21.11%, so any revenue beat or lower-than-expected R&D guidance could lift 42C.SI stock. Conversely, weaker-than-expected wording on commercial rollout or longer clinical timelines would pressure the share price.

Financials and valuation: metrics investors must note

Key ratios show thin liquidity and elevated valuation multiples. Current ratio is 0.47, cash per share is 0.00, and price to sales ratio is 21.12. Book value per share is 0.00, producing a price to book of 412.98, which flags valuation disconnect versus sector averages. Net income per share TTM is -0.01 and free cash flow per share is -0.00, underlining cash burn risk. Investors should compare these figures to healthcare peers on SES before trading the earnings release.

Technical setup and intraday trading cues for 42C.SI stock

Momentum indicators point to a short-term overbought move. RSI is 80.23 and CCI is 151.70, both above typical thresholds. Price sits between the 50-day average 0.15 and 200-day average 0.07, with day range 0.169 to 0.179. Volume today is 6,303,600, near the recent average and sufficient for intraday reactions. A close below the 50-day average would raise short-term risk; a sustained move above 0.18 could attract momentum buyers.

Meyka AI grade and model forecasts for 42C.SI stock

Meyka AI rates 42C.SI with a score out of 100: 56.94 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly: S$0.25, quarterly: S$0.34, and yearly: S$0.85. Against the current price S$0.17, the model implies a monthly upside of 47.06% and a yearly upside of 401.93%. Forecasts are model-based projections and not guarantees.

Final Thoughts

Key takeaways for traders and investors: 42C.SI stock trades at S$0.17 with earnings due 06 Feb 2026, and the report is the immediate intraday catalyst. Financials show negative EPS (-0.01) and weak liquidity (current ratio 0.47), increasing downside risk if management flags higher cash burn. Technicals show overbought momentum (RSI 80.23), which raises the chance of a post-earnings pullback on any miss. On the opportunity side, Meyka AI’s model projects monthly S$0.25 and yearly S$0.85, implying significant upside from today’s level, but those forecasts carry high uncertainty given the company’s loss-making status. We recommend traders size positions carefully around the release, watch guidance and clinical updates, and use stop limits given the stock’s volatility. For a quick reference on market context see the Meyka stock page and recent market commentary

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.